John Paulson’s Purchase of Bausch Health From Carl Icahn – The Special Situations Report Episode #32

Episode Summary

Executive Summary: Episode 32 of the Special Situations Report covered five event-driven themes: Dallas News’s escalating takeover battle, the growing wave of busted-biotech acquisitions, Sinclair’s potential spin-off of non-core assets, and notable insider buying at Suro Capital and Bausch Health. The hosts emphasized governance, capital structure, and insider incentives as key drivers of outcomes in special situations.

Main Topics: Dallas News bidding war and dual-class governance (Priority: 5/5): Dallas News became the episode’s leading takeover story after Hearst’s $15/share offer was challenged by MNG’s $17.50/share bid, but the hosts argued minority holders may still lose because the controlling family has decisive voting power and opposes MNG. Busted biotech acquisitions and CVR structures (Priority: 5/5): The podcast discussed Kevin Tang’s Concentra Biosciences and Zoma Royalty buying distressed biotech names trading below cash, with deals increasingly larger and more frequent. The hosts explained how contingent value rights are often tied to cash runoff or drug milestones and may never pay out. Sinclair’s possible spin-off of non-broadcast assets (Priority: 4/5): Sinclair is exploring a separation of ventures such as Tennis Channel, Digital Remedy, private equity, real estate, and other non-core investments. The segment linked this to a more favorable M&A backdrop for broadcasters and the cyclical nature of advertising tied to elections. Suro Capital and insider-driven NAV discount dynamics (Priority: 4/5): The hosts highlighted CEO Mark Klein’s stock purchase and explained Suro Capital’s strategy of investing pre-IPO, selling after hot IPOs, and returning value through dividends or tender offers. CoreWeave’s decline after quarter-end was noted as a headwind to NAV. Bausch Health insider buying, litigation, and debt burden (Priority: 5/5): John Paulson’s large purchase of Bausch Health shares was dissected, including the fact that it was actually a privately negotiated transaction with Carl Icahn. The company’s debt load, ongoing legal overhangs, and patent risk around Xifaxan framed the investment case.

Key Arguments: Minority shareholders in small-cap or dual-class deals can be disadvantaged when control is concentrated in a family or management group that prefers the original deal terms. Bidding wars do not always result in higher closing prices if control holders refuse competing bids, even when the competing offer is materially superior in economic terms. Busted biotechs often trade below net cash, making them attractive special situations, but high cash burn means value can erode quickly without an activist or acquirer. CVRs in biotech deals may be structured so narrowly or so far into the future that payouts are unlikely, especially if they depend on commercialization milestones or prolonged cash retention. Sinclair’s diverse non-broadcast assets may be better separated from its core media business to improve strategic focus and potentially unlock value. Broadcasting companies may benefit from a more merger-friendly regulatory environment under the current FCC leadership, especially as election-cycle advertising rebounds. Suro Capital’s model is to monetize hot pre-IPO positions after IPO pops rather than hold indefinitely, which can lead to special dividends and periodic tender offers. Bausch Health remains highly leveraged despite operational progress, and insider accumulation may reflect a bet on litigation outcomes, asset value, or strategic restructuring rather than simple operating strength. Carl Icahn’s voting stake in Bausch Health was replaced by economic exposure through cash-settled swaps, showing how control and economics can diverge in special situations.

Data Points: Dallas News initial Hearst offer: $14 per share - Original proposed acquisition price before the bidding war intensified. Dallas News revised Hearst offer: $15 per share - Hearst raised its bid after MNG entered with a higher proposal. Dallas News MNG bid: $16.50 per share - Competing offer that sparked the bidding war. Dallas News MNG final bid mentioned: $17.50 per share - MNG came back with a higher bid after Hearst’s revised proposal. Dallas News last traded price mentioned: $14.93 - Stock price on the last Friday before trading stopped, below the $15 deal price. Territorial Bancorp Hope Bancorp deal: just over $8 per share - Referenced as an example where management stayed with a lower offer. Blue Hill Advisors offer for Territorial Bancorp: $12 per share - Higher competing cash offer that did not prevail. Blue Hill revised offer: $12.50 per share - Second attempt to outbid Hope Bancorp. Dallas News Class B voting power: 55% of total voting power - Robert Decherd’s family/foundation control through high-vote shares. Robert Decherd Class B ownership: 96.2% - Held through the family foundation. Concentra Biosciences deal for Elevation Oncology: $21 million - Example of a busted-biotech acquisition. Concentra Biosciences deal for Kronos Bio: $35 million - Example of a busted-biotech acquisition. Concentra Biosciences deal for IGM Biosciences: $83 million - Example of a busted-biotech acquisition. Zoma Royalty deal for Lava Therapeutics: $30 million - One of two transactions announced by Zoma Royalty. Zoma Royalty deal for Hillivax: $75 million - Second Zoma transaction mentioned in the biotech cleanup theme. Biotech screen lower bound: $100 million market cap - Initial screen used by the host to find companies with more net cash than market cap. Biotech screen upper bound: $300 million market cap - Initial screen range used for net-cash-rich biotechs. Qualified biotech names found: 20 companies - After manual cleanup, the host identified 20 biotech companies meeting the criteria. Qualified biotech names at $50M market cap cutoff: 40+ companies - Lowering the threshold nearly doubled the list. Sinclair Q2 2025 minority investments: $11 million - Results from the ventures business in the quarter. Sinclair Q2 2025 revenue: $784 million - Revenue fell year over year. Sinclair revenue change: -5% year over year - Q2 2025 decline attributed partly to election-cycle seasonality. Suro Capital CEO insider purchase: 14,500 shares - Mark Klein’s open-market purchase despite a strong recent rally. Suro Capital stock move over 3 months: 50% rally - Recent performance cited before discussing the insider buy. Suro Capital stock move over 1 year: 118% increase - Longer-term share price performance mentioned. Suro Capital tender offer price: $4.70 per share - April 2024 tender offer executed when stock traded at a steep NAV discount. Suro Capital NAV discount mentioned: 9% - Based on end-of-Q2 NAV before considering later CoreWeave moves. Bausch Health insider transaction value: nearly $300 million - Large purchase attributed to John Paulson at $9/share. Bausch Health transaction shares: over 34 million shares - Shares acquired from Carl Icahn’s group. Bausch Health Paulson ownership: 90% of outstanding common shares - Post-transaction ownership level cited in the podcast. Bausch Health market cap: $3 billion - Compared against enterprise value and debt burden. Bausch Health enterprise value: $24 billion - Illustrates heavy leverage. Bausch Health prior class action settlement: $1.1 billion - 2019 class action settlement related to earlier conduct. Opt-out plaintiffs’ claims: $4.2 billion - Separate individual claims pursued by some investors. Bausch Health Duract/“Duricet” acquisition value: $63 million - Acquisition of an epigenetic modulation company referenced in the segment. Duract/“Duricet” cash purchase price: $1.75 per share - Per-share consideration in cash. Duract/“Duricet” CVR value: $350 million - Large contingent value right tied to first commercial sale. Duract/“Duricet” CVR horizon: 2040 - Extremely long-dated CVR expiration date.

Pivotal Quotes: "there is a bidding war that might happen" — Asif Surya: Describing the excitement around Dallas News after MNG’s higher offer emerged. "beware of Corporate governance, and especially as it relates to companies with dual-class share structures that allow someone with a limited economic interest to control outcomes" — Tamana Surya: Core takeaway from the Dallas News situation and its implications for minority shareholders. "these are companies where the primary product might have failed a key trial" — Asif Surya: Explaining what busted or zombie biotechs are and why they trade below cash.

Implications: The episode highlights how control, cash balance, and insider incentives can override headline deal prices. Listeners should watch dual-class governance, cash-rich distressed biotechs, and insider buying as signals of possible value creation or shareholder risk.